

[posted as supplied by author]

w1 Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. *Osteoporos Int* 2006/12/20/ 2006;V17(12):1726-1733.)

w2 Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton III LJ et al.. A meta-analysis of prior corticosteroid use and fracture risk. *J Bone Miner Res* 2004;19:893-9.

w3 Kanis JA, Johansson H, Oden A, Johnell O, De Laet C, Eisman JA et al. A family history of fracture and fracture risk: a meta-analysis. *Bone* 2004;35:1029-37.

w4 Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P et al. A meta-analysis of previous fracture and subsequent fracture risk. *Bone* 2004;35:375-82.

w5 Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman JA et al. Smoking and fracture risk: a meta-analysis. *Osteoporos Int* 2005;16:155-62.

w6 De Laet C, Kanis JA, Oden A, Johanson H, Johnell O, Delmas P et al. Body mass index as a predictor of fracture risk: a meta-analysis. *Osteoporos Int* 2005;16:1330-8.

w7 Stevenson M, Lloyd Jones M, De Nigris E, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. *Health Technol Assess* 2005;9:1-160.

w8 Lock CA, Lecouturier J, Mason JM, Dickinson HO. Lifestyle interventions to prevent osteoporotic fractures: a systematic review. *Osteoporos Int* 2006;17:20-8.

w9 Bonaiuti D, Shea B, Iovine R, Negrini S, Robinson V, Kemper HC et al. Exercise for preventing and treating osteoporosis in postmenopausal women. *Cochrane Database Syst Rev* 2002;(3):CD000333.

w10 Boonen S, Laan RF, Barton IP, Watts NB. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. *Osteoporos Int* 2005;16:1291-8.

w11 www.nice.org.uk

w12 Papapoulos SE, Quandt SA, Liberman UA, Hochberg MC, Thompson DE. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. *Osteoporos Int* 2005;16:468-74.

w13 Nguyen ND, Eisman JA, Nguyen TV. Anti-hip fracture efficacy of bisphosphonates: a Bayesian analysis of clinical trials. *J Bone Miner Res* 2006;21:340-9.

w14 O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY. Strontium ranelate for preventing and treating postmenopausal osteoporosis. *Cochrane Database Syst Rev* 2006 Jul 19;3:CD005326.

w15 Seeman E, Crans GG, Diez-Perez A, Pinette KV, Delmas PD. Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. *Osteoporos Int* 2006;17:313-6.

w16 Cranney A, Papaioannou A, Zytaruk N, Hanley D, Adachi J, Goltzman D, Murray T, Hodsman A; Clinical Guidelines Committee of Osteoporosis Canada. Parathyroid hormone for the treatment of osteoporosis: a systematic review. *Canad Med Assoc J* 2006;175:52-9.

w17 Avenell A, Gillespie WJ, Gillespie LD, O'Connell D. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. *Cochrane Database Syst Rev* 2005 Jul 20;:CD000227